Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

Scientists have used artificial intelligence (AI) to create potential new drugs for so-called superbugs – stubborn bacterial infections that can evade existing treatments.